Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

European Recommendations for Transitioning the Care of Patients With Multiple Myeloma Treated With B-Cell Maturation Antigen Bispecific Antibodies From Academic Hospitals to Community-Based Centers and for Outpatient Step-Up Dosing.

EJHaem·2026

Same author

A Retrospective Observational Cohort Study of Lung Cancer Screening Outcomes Among U.S. Blacks and Whites.

JTO clinical and research reports·2025

Same author

A Remotely Delivered Weight Management Service to Support Existing Obesity Services in the UK National Health Service: Preliminary Findings From an Early-Stage Service Evaluation.

JMIR formative research·2025

Same author

HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma.

International journal of molecular sciences·2025

Same author

A remotely-delivered weight management service to support existing obesity services in the UK National Health Service: Preliminary findings from an early-stage service evaluation.

JMIR formative research·2025

Same author

A Remotely Delivered GLP-1RA-Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation.

JMIR formative research·2025

Search research articles

Related Experiment Video

Updated: Sep 10, 2025

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study.

Becky Richards¹, Will Lunt¹, Michael Whitman¹

¹Second Nature, London, United Kingdom.

JMIR Formative Research

|August 21, 2025

Summary

Remote glucagon-like peptide-1 receptor agonist (GLP-1RA) programs show significant weight loss for obesity. These digital interventions are effective, feasible, and cost-saving compared to traditional care.

Keywords:

GLP-1RA behavioral intervention digital health glucagonlike peptide-1 receptor agonist obesity remote health care delivery semaglutide telemedicine weight loss weight management

More Related Videos

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

Published on: November 22, 2024

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

Related Experiment Videos

Last Updated: Sep 10, 2025

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

Published on: November 22, 2024

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

Area of Science:

Obesity Medicine
Digital Health Interventions
Pharmacological Weight Management

Background:

Obesity affects over 890 million adults globally, with traditional interventions often failing long-term.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) demonstrate significant weight loss, but specialist access is limited by cost and capacity.

Purpose of the Study:

To evaluate the effectiveness, feasibility, acceptability, and cost-effectiveness of a 12-month remote GLP-1RA-supported weight management program.
To compare outcomes between tirzepatide and semaglutide within this remote program.

Main Methods:

Retrospective analysis of 339 participants in a 12-month remote weight management program using tirzepatide or semaglutide.
Program combined medication, app-based support, dietitian coaching, and clinical oversight with phased behavior change techniques.
Primary outcomes: mean weight change and achievement of ≥10% and ≥15% weight loss; secondary outcomes: behavioral changes, side effects, acceptability, feasibility, and cost-effectiveness.

Main Results:

Mean weight loss at 12 months was -22.9 kg with tirzepatide and -18.1 kg with semaglutide (P<0.05).
≥10% weight loss achieved by 95.2% (tirzepatide) and 83.1% (semaglutide); ≥15% by 83.7% and 56.2%, respectively.
Significant reductions in inactivity and initial side effects (nausea, fatigue, constipation) were observed, with increased reporting of no side effects.

Conclusions:

Remotely delivered GLP-1RA programs achieve weight loss comparable to clinical trials and offer significant cost savings (10-70%) versus traditional UK services.
Both tirzepatide and semaglutide demonstrated clinically significant weight loss with good safety and positive behavioral changes.
Digital delivery models are feasible and effective for expanding access to obesity treatment in resource-constrained systems.